Pharsight

Drugs that contain Bupropion Hydrobromide

1. Aplenzin patents expiration

Can you believe APLENZIN received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7569610 BAUSCH Modified release formulations of a bupropion salt
Jun, 2026

(2 years from now)

US7241805 BAUSCH Modified release formulations of a bupropion salt
Jun, 2026

(2 years from now)

US7645802 BAUSCH Bupropion hydrobromide and therapeutic applications
Jun, 2026

(2 years from now)

US7572935 BAUSCH Modified release formulations of a bupropion salt
Jun, 2026

(2 years from now)

US7585897 BAUSCH Modified release formulations of a bupropion salt
Jun, 2026

(2 years from now)

US7662407 BAUSCH Modified release formulations of a bupropion salt
Jun, 2026

(2 years from now)

US7671094 BAUSCH Bupropion hydrobromide and therapeutic applications
Jun, 2026

(2 years from now)

US7649019 BAUSCH Modified release formulations of a bupropion salt
Jun, 2026

(2 years from now)

Market Authorisation Date: 23 April, 2008

Treatment: Treatment of major depressive disorder by dosing at intervals of 24 hours

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of APLENZIN before it's drug patent expiration?
More Information on Dosage

APLENZIN family patents

Family Patents